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Summary The true survival rates for the various forms of childhood cancer are best determined from a
population-based study rather than from the results of clinical trials. Population-based survival rates have
been calculated for four periods between 1956 and 1980 in Queensland. There was a significant improvement
in survival for children who developed cancer after 1973 compared with those diagnosed before this date.
There has however been no significant improvement in the survival rate for childhood cancer overall, or for
acute lymphoblastic leukaemia since 1973. Over the 25 year period significant trends in survival rates were
seen in acute lymphoblastic leukaemia, non-Hodgkin's lymphoma, Hodgkin's disease, Wilms' tumour,
medulloblastoma, and retinoblastoma. No such trend was seen for acute non-lymphoblastic leukaemia,
neuroblastoma, rhabdomyosarcoma, juvenile or anaplastic astrocytoma, brain stem glioma, histiocytosis X, or
bone tumours. There is a need for continuing research into better methods of treatment ofchildhood cancer.
Cancer is an important cause of mortality in
children. In the 1-14 year age group it comes
second only to accidents as a cause of death. There
have been many changes in the management of
both leukaemias and solid tumours in the past 30
years. Many of these have been reported, together
with results, in the form of clinical trials. Nearly all
such trials however require some degree of selection
of cases and very little information is available on
the survival rates of unselected series of patients,
particularly for the most recent years. One large
study has been published on childhood cancer
survival in Great Britain (Draper et al., 1982), but
only includes children who were diagnosed before
1975. Another series from the United States
included only white children from the years 1955-
71 (Myers et al., 1975). The present study examines
the trends in survival rates of childhood cancer in
Queensland during the 25 year period from 1956 to
1980.
Methods
Information on cases was obtained from the
Queensland Childhood Malignancy Registry
(McWhirter & Bacon, 1981). This is a population
based registry which includes all children with
malignant tumours and also all intracranial
tumours who were under the age of 15 years and
resident in Queensland at the date of incidence.
Although registration is believed to be complete
from 1973 onwards, it is certainly incomplete for
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the period 1956-72. Registration was retrospective
for the earlier period and was obtained from the
records of the two children's hospitals in
Queensland, from the pathology departments of the
Royal Brisbane and Mater Hospitals in Brisbane,
and from the Queensland Radium Institute, the
centre for radiotherapy for this state. Death
certificates were not used as a source of
ascertainment. A total of 1,030 patients were
registered during the 25 year period 1956-80.
Follow-up information is obtained mainly by the
use of questionnaires which are sent annually for
the first 5 years, then at 7, 10 and 15 years to the
doctor or clinic believed to be caring for the
patient. Many of the cases from the earlier years of
this study have been followed up by the
Queensland Radium Institute which has had an
effective information system in operation for many
years. In a few cases dates of death were obtained
from the Registrar-General. The cases were divided
into four groups according to their date of
presentation. The period of incomplete registration
was divided into two, so as to produce two groups
of approximately equal size; Group A contained
202 patients from the period 1956-66, and Group B
249 patients from the period 1967-72. The patients
from 1973 onwards were similarly allocated to two
groups; Group C (1973-76) contained 252 patients,
and Group D (1977-80) 275 patients. Survival data
was examined using standard methods of life table
analysis (Peto et al., 1977). The P values in Table V
are based on 3 degrees of freedom for heterogeneity
(2 for histiocytosis X because there were no cases of
this tumour in Group A), and on one degree of
freedom for trend.
Almost all the cases were seen at one or other of
the major centres in Brisbane, at least for initial
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assessment and treatment planning. Because of the
vast distances in this state, however, some of the
chemotherapy was given, under supervision from
the major centre, by the local doctor or at the local
hospital.
Results
The number of cases in each group and the
percentage on whom at least some follow-up
information was available are shown in Table I.
Table II shows the numbers of cases of each of the
tumour types studied in the four groups. Tables III
and IV give the survival rates at 1, 3, and 5 years,
and, for Groups A and B, at 10 years. No cases of
neuroblastoma, ependymoma, or histiocytosis X in
Group D were yet at risk at 5 years from the date
of incidence so that 5-year survival rates could not
be calculated for them. The marked improvement
in survival rates for childhood cancer overall
Table I Numbers of cases and proportion followed
up
Years of No. %followed
Group presentation cases up
A 1956-66 232 87.1
B 1967-72 270 92.2
C 1973-76 253 98.0
D 1977-80 275 98.5
Table II Numbers of cases by diagnosis
Number ofcases
in each group
Group A B C D
ALL 45 61 72 74
ANLL 6 11 6 14
Non-Hodgkin's lymphoma 10 22 12 20
Hodgkin's disease 1 8 17 11
Neuroblastoma 18 16 20 18
Rhabdomyosarcoma 5 3 5 13
Wilms' tumour 18 12 18 17
Juvenile astrocytoma 24 16 9 8
Anaplastic astrocytoma 8 8 4 11
Other astrocytoma 4 8 8 2
Medulloblastoma 5 8 13 11
Ependymoma 6 8 4 4
Brain stem glioma 10 13 7 6
Retinoblastoma 1 8 12 9
Bone tumours 15 15 11 11
Histiocytosis X 0 3 5 10
All Neoplasms 202 249 252 275
occurred entirely during the 10-year period from
1967 to 1976. There was no difference in survival
between Groups A and B (X2 =0.65, P>0.4), or
between Groups C and D (X2 =0.08, P>0.7).
Nevertheless the x2 values for both heterogeneity
and trend are highly significant (Table V). Strati-
fication by diagnostic group made no appreciable
difference; the corresponding values for x2 after
stratification were 64.4 and 54.7.
Table III Survival rates for selected malignancies 1956-72
Group A (1956-66) Group B (1967-72)
Disease ly 3y Sy JOy Jy 3y Sy JOy
ALL 33.3 8.9 2.2 0.0 68.9 14.8 6.6 4.9
ANLL 16.7 0.0 0.0 0.0 27.3 0.0 0.0 0.0
Non-Hodgkin's lymphoma 40.0 30.0 30.0 30.0 36.4 13.6 13.6 13.6
Hodgkin's disease 100.0 100.0 100.0 100.0 87.5 62.5 37.5 37.5
Neuroblastoma 38.9 22.2 22.2 22.2 37.5 31.3 31.3 31.3
Rhabdomyosarcoma 20.0 20.0 20.0 20.0 66.7 66.7 66.7 66.7
Wilms' tumour 61.1 38.9 38.9 38.9 75.0 75.0 75.0 75.0
Juvenile astrocytoma 91.7 79.2 79.2 79.2 81.3 62.5 62.5 56.3
Anaplastic astrocytoma 25.0 12.5 12.5 12.5 75.0 50.0 37.5 37.5
Other astrocytoma 75.0 75.0 75.0 25.0 87.5 75.0 75.0 62.5
Medulloblastoma 60.0 20.0 20.0 20.0 25.0 12.5 12.5 12.5
Ependymoma 66.7 50.0 50.0 50.0 87.5 37.5 25.0 25.0
Brain stem glioma 40.0 30.0 30.0 30.0 23.1 7.7 7.7 7.7
Retinoblastoma 100.0 0.0 0.0 0.0 100.0 87.5 87.5 87.5
Bone tumours 60.0 40.0 40.0 33.3 53.3 26.7 13.3 13.3
Histiocytosis X 33.3 33.3 33.3 33.3
All tumours 50.0 33.2 31.2 28.7 60.6 34.5 29.7 28.5CHILDHOOD CANCER SURVIVAL IN QUEENSLAND 515
Table IV Survival rates for selected malignancies 1973-80
Group C (1973-76) Group D (1977-S0)
Disease Jy 3y 5y Jy 3y 5y
ALL 81.9 58.3 45.8 82.4 61.6 47.9
ANLL 66.7 16.7 16.7 57.1 19.1 0.0
Non-Hodgkin's lymphoma 83.3 75.0 58.3 65.0 60.0 60.0
Hodgkin's disease 100.0 100.0 100.0 100.0 100.0 100.0
Neuroblastoma 55.0 35.0 30.0 50.0 22.2
Rhabdomyosarcoma 60.0 20.0 20.0 53.9 46.2 46.2
Wilms' tumour 72.2 66.7 61.1 94.1 80.9 80.9
Juvenile astrocytoma 77.8 77.8 77.8 100.0 72.9 72.9
Anaplastic astrocytoma 25.0 25.0 25.0 63.6 27.3 27.3
Other astrocytoma 87.5 62.5 62.5 100.0 50.0 50.0
Medulloblastoma 69.2 46.2 38.5 90.9 63.6 63.6
Ependymoma 100.0 25.0 25.0 100.0 -
Brain stem glioma 28.9 0.0 0.0 50.0 0.0 0X0
Retinoblastoma 91.7 91.7 91.7 100.0 100.0 100.0
Bone tumours 100.0 54.6 36.4 90.9 52.5 52.5
Histiocytosis X 100.0 100.0 100.0 80.0 70.0
All tumours 77.4 59.5 53.2 76.4 57.1 52.0
Table V Survival analysis
Disease
Chi-squared and P valuefor
Heterogeneity Trend
ALL
ANLL
Non-Hodgkin's lymphoma
Hodgkin's disease
Neuroblastoma
Rhabdomyosarcoma
Wilms' tumour
Juvenile astrocytoma
Anaplastic astrocytoma
Other astrocytoma
Medulloblastoma
Ependymoma
Brain stem glioma
Retinoblastoma
Bone tumours
Histiocytosis X
All tumours
85.9856
5.6998
11.3471
22.4815
0.6954
2.2025
7.5180
1.7989
3.0585
1.7716
7.2160
0.7905
2.0648
13.7936
4.2815
6.31
55.2690
The greatest improvement in survival occurred in
acute lymphoblastic leukaemia (ALL). The 5-year
survival rate increased from 2.2% in Group A to
6.6% in Group B (Figure 1) and to 45% in Group
C, but only to 48% in Group D (Figure 2). x2 for
Group C versus Group D=0.14, P>0.7. Significant
trends in survival rates over the 4 groups were also
seen in non-Hodgkin's lymphoma, Hodgkin's
disease, Wilms' tumour, medulloblastoma, retino-
blastoma and bone tumours (Table V).
<0.0005
NS
<0.01
<0.0005
NS
NS
NS
NS
NS
NS
NS
NS
NS
<0.005
NS
<0.05
72.1547
3.8016
7.0627
9.2631
0,0334
0.4351
5.5249
0.0101
0.1695
0.0688
5.3133
0.2965
0.2616
4.3022
1.7980
0.9543
<0.0005
NS
<0.01
<0.005
NS
NS
<0.025
NS
NS
NS
<0.025
NS
NS
<0.05
NS
NS
<0.0005 46.5241 <0.0005
Discussion
It is almost certain that some of the patients not
registered, or lost to follow-up in the period before
1972 were those who died early, so that survival
rates calculated for Groups A and B may be
slightly higher than the true values. The number of
such patients must however be small. Until recently,
specialist treatment was not available for children
outside the capital, Brisbane. Cases were therefore- Group A
Group B
Time (months)
Figure 1 Survival in ALL, 1956-1972.
--------- Group C
Group D
12 24 36 48
Time (months)
Figure 2 Survival in ALL, 1973-1980.
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generally transferred to one of the major hospitals
in Brisbane at an early stage in their illness. In
interpreting the 5-year survival rate in Group D, it
is important to appreciate that this is an estimate
made from life-table analysis. Most of the patients
in this group have not yet had 5 years of follow-up.
The 5-year survival rates for Group D should
therefore be regarded as tentative. It -was felt
nevertheless that they should be included in an
attempt to provide up-to-date information.
This study confirms the improvement in survival
which has been reported for childhood cancer as a
whole as well as for several individual types of
tumour (Draper et al., 1982; Myers et al., 1975).
The survival rates quoted in these two series may
be compared with those in Tables III and IV, and
are generally of the same order as those for the
present series (see Table VI).
The most important advance, in terms of
reduction of overall cancer mortality, has been the
increase in the survival rate for ALL. Before 1970
this disease was almost invariably fatal. Almost half
the children in Group C survived 5 years from the
time of diagnosis, but there was virtually no further
gain in survival for those in Group D. The develop-
ment of carefully planned chemotherapy including
multiple drug induction and consolidation regimes,
CNS prophylaxis with combined cranial radiation
and intrathecal chemotherapy, and better
supportive care such as vigorous treatment of
actual and potential infection have all contributed
to the improvement. For acute non-lymphoblastic
leukaemia (ANLL), there has been a considerable
increase in the proportion of children attaining an
initial remission, but the subsequent relapse rate
remains high (Wilbur et al., 1981). As a result,
there are still very few long-term survivors.
The introduction of effective chemotherapy, with
or without radiotherapy, for non-Hodgkin's
lymphoma (Wollner et al., 1976) has greatly
improved long-term survival in this condition, and
most children who are alive at 4 years from
diagnosis are likely to be cured of their disease
(Anderson et al., 1983). Current methods of
treatment for Hodgkin's disease, including
combined chemotherapy and extended field radio-
therapy are now producing extremely high cure
rates, probably accompanied by less morbidity than
was seen with older methods of treatment (Jenkin
& Berry, 1980). Despite numerous attempts to
improve the prognosis for neuroblastoma, long
term results have remained disappointing, especially
in older children who tend to have advanced
disease at the time ofdiagnosis.
In contrast with the results which might have
been expected from the literature on the use of
chemotherapy in rhabdomyosarcoma (Bizer, 1980),
there was no significant improvement in the
survival rates for this tumour. The number of cases
is, however, small. This together with the fact that
the different histological criteria may have been
applied during the 25 year period must cast slight
doubt on the accuracy of the survival rates in
Groups A and B. The use of chemotherapy with
agents such as vincristine, dactinomycin, and cyclo-
phosphamide has reduced the need for radical
surgery, especially in embryonal rhabdomyo-
sarcoma, so that the long term morbidity in the
survivors is probably less than previously.
There has been a substantial improvement in the
survival rate for Wilms' tumour. This is in keeping
with published results (D'Angio et al., 1981) and
reflects the universal use of chemotherapy,
especially vincristine and dactinomycin, in this
tumour. The application of radiotherapy has also
been refined, and it is now clear that radiotherapy
Table VI 5-year survival rates in Queensland, Great Britain and U.S. whites
Queensland Great Britain Manchester U.S. whites
Tumour type 1967-72 1962-70 1954-73 1965-69
ALL 7 12 6
Non-Hodgkin's lymphoma 14 20 24 20
Hodgkin's disease 38 53 56 66
Neuroblastoma 31 18 14 22
Rhabdomyosarcoma 67 20 21 36a
Wilms' tumour 75 34 44 60
Juvenile astrocytoma 63 71
Medulloblastoma 13 18 32 32
Ependymoma 13 23 25
Retinoblastoma 88 85 83 91
Bone tumours 13 22 16 22
All cancers 30 34
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is not required in cases where the disease is
confined to the kidney (D'Angio et al., 1981).
Amongst the brain tumours there is a mixed
picture dependent on the morphological diagnosis.
There is an obvious difference in the survival
pattern between juvenile astrocytomas of low
malignancy and the anaplastic variety. This has
been noted previously (Draper et al., 1982; Bloom,
1982a), and confirms the value of accurate histo-
logical diagnosis. In neither type was a significant
trend in survival rates observed. Unlike the astro-
cytomas, there has been a significant improvement
in survival for medulloblastoma. Changes in radio-
therapy techniques have led to higher cure rates for
this tumour (Berry et al., 1981), and adjuvant
chemotherapy may be resulting in further improve-
ment, with 5-year survival rates of -70% being
reported (Bloom, 1982b). Some of the patients with
medulloblastoma in Group D received various
forms of chemotherapy in addition to surgery and
radiotherapy. Although some of the patients with
ependymoma also received chemotherapy, it is not
yet possible to assess the effect of this because of
the relative rarity of this tumour. In general, the
patients with brain stem glioma were treated by
radiotherapy alone and the results were extremely
poor. Although there were some long-term
survivors in Groups A and B, the longest survival
amongst Groups C and D was 26 months.
The outlook in retinoblastoma was good in the
later 3 groups and survival rates were similar to
those in Britain (Draper et al., 1982). The survival
rates for bone tumours appear quite high in
Groups C and D. Comparison with other series is
however difficult since the pattern of incidence is
quite different from that in other reported series,
Ewing's tumour being much commoner than osteo-
sarcoma in Queensland (McWhirter & Bacon,
1981). The reason for this is not known. In histio-
cytosis X, there appears to have been some
improvement in survival, but the trend was not
statistically significant, perhaps because of the small
numbers. The possibility also exists that in Group
B there may have been some under-ascertainment
of cases of localised disease (eosinophilic granu-
loma), so that the true survival rate for this period
may have been higher than Table III would
indicate.
Clinical trials almost invariably involve some
initial selection of patients depending on the
presence or absence of various clinical or
laboratory features. Some patients or their parents
may refuse consent to be entered into a trial, or an
individual case may be judged unsuitable for one
reason or another. Additionally, patients may be
excluded later from the trial because of relapse,
violation of protocol, or an ill-defined reason such
as "non-evaluability". A population-based study of
survival therefore gives a more realistic assessment
of current survival rates and the changes which
have occurred over a period of time. The results of
this study indicate that the outlook for children
with cancer improved considerably around the late
1960s or early 1970s. Relatively little further
improvement has occurred in the later 1970s. Over
the 25 year period significant improvement
occurred in the survival rates of ALL, non-
Hodgkin's lymphoma, Hodgkin's disease, Wilms'
tumour, medulloblastoma, and retinoblastoma. The
results of treatment of some tumours such as
neuroblastoma, anaplastic astrocytoma, and brain
stem glioma remain poor, while ALL is still an
important cause of death in children. There is
therefore a need for continuing research into the
treatment of childhood cancer, in the hope of
producing better results in this latter group. The
results of clinical trials in some selected groups of
patients should give no cause for complacency.
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